The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

F Handle; M Ruhr; G Schaefer; N Lorito; J Hoefer; M Gruber; F Guggenberger; FR Santer; Rute Barbosa Marques; Wytske van Weerden; F Claessens; HHH Erb; Z Culig

doi:10.1158/1535-7163.Mct-18-0508

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

F Handle, M Ruhr, G Schaefer, N Lorito, J Hoefer, M Gruber, F Guggenberger, FR Santer, Rute Barbosa Marques, Wytske van Weerden, F Claessens, HHH Erb, Z Culig

Urology

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2722-2731
Number of pages	10
Journal	Molecular Cancer Therapeutics
Volume	17
Issue number	12
DOIs	https://doi.org/10.1158/1535-7163.Mct-18-0508
Publication status	Published - 2018

Research programs

EMC MM-03-49-01

Access to Document

10.1158/1535-7163.Mct-18-0508

http://hdl.handle.net/1765/112871

Cite this

Handle, F., Ruhr, M., Schaefer, G., Lorito, N., Hoefer, J., Gruber, M., Guggenberger, F., Santer, FR., Barbosa Marques, R., van Weerden, W., Claessens, F., Erb, HHH., & Culig, Z. (2018). The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. Molecular Cancer Therapeutics, 17(12), 2722-2731. https://doi.org/10.1158/1535-7163.Mct-18-0508

@article{a82fbe6b1e16478aacbc366a9bb6f095,

title = "The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models",

author = "F Handle and M Ruhr and G Schaefer and N Lorito and J Hoefer and M Gruber and F Guggenberger and FR Santer and {Barbosa Marques}, Rute and {van Weerden}, Wytske and F Claessens and HHH Erb and Z Culig",

year = "2018",

doi = "10.1158/1535-7163.Mct-18-0508",

language = "Undefined/Unknown",

volume = "17",

pages = "2722--2731",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

Handle, F, Ruhr, M, Schaefer, G, Lorito, N, Hoefer, J, Gruber, M, Guggenberger, F, Santer, FR, Barbosa Marques, R, van Weerden, W, Claessens, F, Erb, HHH & Culig, Z 2018, 'The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models', Molecular Cancer Therapeutics, vol. 17, no. 12, pp. 2722-2731. https://doi.org/10.1158/1535-7163.Mct-18-0508

TY - JOUR

T1 - The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

AU - Handle, F

AU - Ruhr, M

AU - Schaefer, G

AU - Lorito, N

AU - Hoefer, J

AU - Gruber, M

AU - Guggenberger, F

AU - Santer, FR

AU - Barbosa Marques, Rute

AU - van Weerden, Wytske

AU - Claessens, F

AU - Erb, HHH

AU - Culig, Z

PY - 2018

Y1 - 2018

U2 - 10.1158/1535-7163.Mct-18-0508

DO - 10.1158/1535-7163.Mct-18-0508

M3 - Article

SN - 1535-7163

VL - 17

SP - 2722

EP - 2731

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 12

ER -